A Johns Hopkins team has shown that antiviral-loaded, mucus-penetrating particles can be used for vaginal delivery to help prevent herpes simplex virus infection. The team thinks the particles have potential to deliver drugs to treat a variety of mucosal diseases, and Kala Pharmaceuticals has licensed the IP.